These findings indicate that mTORC2 signaling can contribute to PTEN-deleted prostate cancer growth, and that mTORC2 inhibition may be efficacious in the clinic against prostate cancers with PTEN loss [190]. The gene discussed is PTEN; the disease is prostate cancer.